ILMN vs. PACB

Last updated Jun 4, 2026

ILMN (Illumina, Inc.) and PACB (Pacific Biosciences of California, Inc.) are both stocks. Both operate in the Diagnostics & Research industry within the Healthcare sector. Over the past 10 years, ILMN returned 1.90%/yr vs -16.34%/yr for PACB. At a 0.39 correlation, their price movements are largely independent.

Performance

ILMN vs. PACB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Illumina, Inc. (ILMN) and Pacific Biosciences of California, Inc. (PACB). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ILMN achieves a 30.32% return, which is significantly higher than PACB's -15.51% return. Over the past 10 years, ILMN has outperformed PACB with an annualized return of 1.90%, while PACB has yielded a comparatively lower -16.34% annualized return.

ILMN

• 1D: 5.16%
• 1M: 22.64%
• YTD: 30.32%
• 6M: 33.59%
• 1Y: 108.88%
• 3Y*: -5.36%
• 5Y*: -15.92%
• 10Y*: 1.90%

PACB

• 1D: 0.00%
• 1M: 1.94%
• YTD: -15.51%
• 6M: -34.98%
• 1Y: 50.48%
• 3Y*: -51.07%
• 5Y*: -42.94%
• 10Y*: -16.34%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ILMN vs. PACB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ILMN Illumina, Inc.	30.32%	-1.85%	-1.34%	-31.14%	-46.85%	2.82%	11.53%	10.61%	37.27%	70.64%
PACB Pacific Biosciences of California, Inc.	-15.51%	2.19%	-81.35%	19.93%	-60.02%	-21.13%	404.67%	-30.54%	180.30%	-30.53%

Correlation

The correlation between ILMN and PACB is 0.48, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.48
Correlation (3Y) Calculated over the trailing 3-year period	0.48
Correlation (5Y) Calculated over the trailing 5-year period	0.51
Correlation (10Y) Calculated over the trailing 10-year period	0.43
Correlation (All Time) Calculated using the full available price history since Oct 28, 2010	0.39

The correlation between ILMN and PACB shifts across timeframes, from 0.39 (all time) to 0.51 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap ILMN : $26.32B PACB : $483.19M
EPS ILMN : $5.48 PACB : -$0.43
PS Ratio ILMN : 6.06 PACB : 2.98
PB Ratio ILMN : 8.69 PACB : 4.61
Total Revenue (TTM) ILMN : $4.39B PACB : $160.03M
Gross Profit (TTM) ILMN : $2.93B PACB : $59.34M
EBITDA (TTM) ILMN : $1.39B PACB : -$146.34M

Return for Risk

ILMN vs. PACB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ILMN

ILMN Risk / Return Rank: 88
ILMN Sharpe Ratio Rank: 90
ILMN Sortino Ratio Rank: 90
ILMN Omega Ratio Rank: 87
ILMN Calmar Ratio Rank: 88
ILMN Martin Ratio Rank: 86

PACB

PACB Risk / Return Rank: 60
PACB Sharpe Ratio Rank: 60
PACB Sortino Ratio Rank: 64
PACB Omega Ratio Rank: 58
PACB Calmar Ratio Rank: 59
PACB Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ILMN vs. PACB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Illumina, Inc. (ILMN) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ILMN	PACB	Difference
Sharpe ratio Return per unit of total volatility	2.33	0.57	+1.76
Sortino ratio Return per unit of downside risk	3.26	1.45	+1.81
Omega ratio Gain probability vs. loss probability	1.39	1.16	+0.24
Calmar ratio Return relative to maximum drawdown	4.27	0.87	+3.39
Martin ratio Return relative to average drawdown	9.67	1.71	+7.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ILMN vs. PACB - Sharpe Ratio Comparison

The current ILMN Sharpe Ratio is 2.33, which is higher than the PACB Sharpe Ratio of 0.57. The chart below compares the historical Sharpe Ratios of ILMN and PACB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ILMN	PACB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.33	0.57	+1.76
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.35	-0.46	+0.11
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.05	-0.19	+0.24
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	-0.17	+0.32

Drawdowns

ILMN vs. PACB - Drawdown Comparison

The maximum ILMN drawdown since its inception was -96.14%, roughly equal to the maximum PACB drawdown of -98.22%. Use the drawdown chart below to compare losses from any high point for ILMN and PACB.

Drawdown Indicators

	ILMN	PACB	Difference
Max Drawdown Largest peak-to-trough decline	-96.14%	-98.22%	+2.08%
Max Drawdown (1Y) Largest decline over 1 year	-25.66%	-58.05%	+32.39%
Max Drawdown (3Y) Largest decline over 3 years	-65.68%	-93.52%	+27.84%
Max Drawdown (5Y) Largest decline over 5 years	-86.23%	-97.47%	+11.24%
Max Drawdown (10Y) Largest decline over 10 years	-86.23%	-98.22%	+11.99%
Current Drawdown Current decline from peak	-66.52%	-96.91%	+30.39%
Average Drawdown Average peak-to-trough decline	-40.37%	-70.50%	+30.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.30%	29.66%	-18.36%

Volatility

ILMN vs. PACB - Volatility Comparison

The current volatility for Illumina, Inc. (ILMN) is 9.58%, while Pacific Biosciences of California, Inc. (PACB) has a volatility of 27.68%. This indicates that ILMN experiences smaller price fluctuations and is considered to be less risky than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ILMN	PACB	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.58%	27.68%	-18.10%
Volatility (6M) Calculated over the trailing 6-month period	29.23%	56.30%	-27.07%
Volatility (1Y) Calculated over the trailing 1-year period	46.92%	89.27%	-42.35%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.66%	94.33%	-48.67%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	42.17%	84.65%	-42.48%

Dividends

ILMN vs. PACB - Dividend Comparison

Neither ILMN nor PACB has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ILMN and PACB in my portfolio?

ILMN and PACB have a correlation of 0.48, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ILMN or PACB?

PACB has higher volatility (27.68%) compared to ILMN (9.58%). In terms of maximum drawdown, ILMN dropped -96.14% vs PACB's -98.22%.

Which has better risk-adjusted returns?

ILMN currently has the higher Sharpe Ratio (2.33 vs 0.57), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.